GleamWall
中文EN

GHRS GH Research PLC IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1855129 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-21.0%
ROA-20.3%
ROIC (approx.)-86.0%
Asset turnover—

Leverage & solvency

Liabilities / assets3.0%
Debt / equity0.00x
Current ratio34.13x
Interest coverage-131.14x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-31
Income statement
Revenue————————
R&D expense$11.39M$10.57M$8.96M$7.85M$8.21M$8.40M$9.76M$8.66M
SG&A expense$5.33M$6.00M$5.75M$4.88M$4.74M$4.22M$3.46M$2.87M
Operating income-$16.72M-$16.57M-$14.70M-$12.73M-$12.94M-$12.62M-$13.22M-$11.53M
Interest expense$90,000$21,000$174,000$178,000$179,000$181,000$178,000$179,000
Pretax income-$14.14M-$14.02M-$9.29M-$10.81M-$8.80M-$12.11M-$10.38M-$7.67M
Income tax$0$0$0$0$0$0$0$0
Net income-$14.14M-$14.02M-$9.29M-$10.81M-$8.80M-$12.11M-$10.38M-$7.67M
EBITDA-$16.63M-$16.48M-$14.62M-$12.66M-$12.87M-$12.54M-$13.14M-$11.45M
EPS (basic)—-0.23-0.15-0.19—-0.23-0.20-0.15
EPS (diluted)—-0.23-0.15-0.19—-0.23-0.20-0.15
Balance sheet
Cash & equivalents$246.25M$249.65M$253.87M$244.95M$100.79M$90.06M$87.13M$77.48M
Current assets$285.98M$294.79M$293.88M$294.67M$154.22M$154.95M$152.91M$160.48M
PP&E, netmay include right-of-use assets (IFRS)$620,000$692,000$739,000$705,000$748,000$859,000$896,000$975,000
Total assets$288.23M$302.02M$313.43M$320.45M$188.27M$199.61M$206.98M$217.58M
Current liabilities$8.38M$10.41M$9.97M$9.92M$8.95M$9.79M$7.80M$7.28M
Total liabilities$8.53M$10.62M$10.25M$10.24M$9.32M$10.24M$8.30M$7.84M
Shareholders' equity$279.70M$291.40M$303.18M$310.21M$178.95M$189.37M$198.68M$209.75M
Cash flow statement
Operating cash flow-$12.33M-$13.68M-$8.97M-$8.57M-$10.45M-$12.31M-$9.94M-$9.60M
Capital expenditure$19,000$39,000$59,000$4,000$25,000$4,000$8,000$12,000
Free cash flow-$12.35M-$13.72M-$9.03M-$8.58M-$10.47M-$12.31M-$9.94M-$9.61M
Investing cash flow$8.84M$9.78M$15.71M$11.84M$21.33M$15.28M$19.73M$8.79M
Financing cash flow-$68,000-$66,000-$1.07M$140.86M-$59,000-$60,000-$114,000-$71,000
Depreciation & amortization$88,000$89,000$82,000$76,000$78,000$79,000$78,000$80,000
Stock-based compensation$2.66M$2.30M$1.90M$1.64M$759,000$300,000-$100,000$277,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.